C4 Therapeutics Inc.
10/11/2024 | Press release | Distributed by Public on 10/11/2024 14:10
Management Change/Compensation Form 8 K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 7, 2024, the Board of Directors of C4 Therapeutics, Inc. (the "Company") approved Amendment No. 1 (the "Plan Amendment") to the Company's 2020 Stock Option and Incentive Plan (the "2020 Plan") to provide that in no event may the Administrator (as defined in the Plan) exercise its discretion to reduce the exercise price of outstanding stock options or stock appreciation rights or effect repricing through cancellation and re-grants or cancellation of stock options or stock appreciation rights in exchange for cash or other awards, without prior stockholder approval. The Plan Amendment is effective immediately and is not subject to approval by our stockholders.
The foregoing description of the Plan Amendment is qualified in its entirety by the full text of the Plan Amendment, a copy of which is attached as Exhibit 10.1 hereto and incorporated by reference herein.